AR088244A1 - oxMIF COMO MARCADOR DE DIAGNOSTICO - Google Patents
oxMIF COMO MARCADOR DE DIAGNOSTICOInfo
- Publication number
- AR088244A1 AR088244A1 ARP120103713A ARP120103713A AR088244A1 AR 088244 A1 AR088244 A1 AR 088244A1 AR P120103713 A ARP120103713 A AR P120103713A AR P120103713 A ARP120103713 A AR P120103713A AR 088244 A1 AR088244 A1 AR 088244A1
- Authority
- AR
- Argentina
- Prior art keywords
- oxmif
- mif
- refers
- diagnostic
- diagnostic marker
- Prior art date
Links
- 239000003550 marker Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 102000028589 Rab4 Human genes 0.000 abstract 1
- 102000028677 Rab9 Human genes 0.000 abstract 1
- 108050007276 Rab9 Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 108010044923 rab4 GTP-Binding Proteins Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545042P | 2011-10-07 | 2011-10-07 | |
| US201261624943P | 2012-04-16 | 2012-04-16 | |
| US201261668841P | 2012-07-06 | 2012-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088244A1 true AR088244A1 (es) | 2014-05-21 |
Family
ID=46980957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103713A AR088244A1 (es) | 2011-10-07 | 2012-10-05 | oxMIF COMO MARCADOR DE DIAGNOSTICO |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9958456B2 (enExample) |
| EP (1) | EP2748613B1 (enExample) |
| JP (1) | JP2014530360A (enExample) |
| AR (1) | AR088244A1 (enExample) |
| AU (1) | AU2012320597C1 (enExample) |
| HK (1) | HK1198591A1 (enExample) |
| TW (1) | TW201321408A (enExample) |
| WO (1) | WO2013050453A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013050453A1 (en) | 2011-10-07 | 2013-04-11 | Baxter Healthcare S.A. | Oxmif as a diagnostic marker |
| AU2013202693B2 (en) * | 2012-04-16 | 2015-01-22 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics |
| KR20150029017A (ko) * | 2012-07-10 | 2015-03-17 | 박스터 헬쓰케어 에스에이 | 항-mif 면역조직화학 |
| US9536304B2 (en) * | 2013-08-30 | 2017-01-03 | Dairy Quality Inc. | Determining pathogens based on an image of somatic cells in a fluid sample |
| JP6615753B2 (ja) * | 2013-10-04 | 2019-12-04 | レジニアス リミテッド | 細胞療法のためのバイオマーカー |
| AU2015206178A1 (en) * | 2014-01-03 | 2016-07-07 | Baxalta GmbH | Anti-MIF immunohistochemistry |
| WO2016026956A1 (en) * | 2014-08-22 | 2016-02-25 | Baxalta GmbH | Detection of cho-mif contaminations |
| JP2021526820A (ja) * | 2018-06-07 | 2021-10-11 | オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 癌治療のための抗ｏｘＭＩＦ／抗ＣＤ３抗体 |
| CN115943160A (zh) * | 2019-12-06 | 2023-04-07 | 翁科奥内研发有限责任公司 | 抗oxMIF/抗CD3双特异性抗体构建体 |
| WO2022167474A1 (en) * | 2021-02-03 | 2022-08-11 | Oncoone Research & Development Gmbh | ANTI-oxMIF RADIOIMMUNOCONJUGATE |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4299814A (en) | 1979-05-25 | 1981-11-10 | Monsanto Company | Radioimmunoassay of MIF |
| JPH0672158B2 (ja) * | 1984-05-24 | 1994-09-14 | チバ−ガイギ− アクチエンゲゼルシヤフト | 精製されたヒトマクロファージ遊走阻止因子 |
| US4946674A (en) | 1984-10-05 | 1990-08-07 | Bioferon Biochemische Substanzen Gmbh & Co. | Process for treatment of rheumatic diseases |
| US4708937A (en) | 1984-10-15 | 1987-11-24 | Brigham & Women's Hospital | Purified migration inhibitory factor also having colony stimulating factor activity |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3789413T2 (de) | 1986-10-03 | 1994-07-28 | Ciba Geigy Ag | Lymphokin-ähnliche Peptide. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990011301A1 (en) | 1989-03-17 | 1990-10-04 | Genetics Institute, Inc. | Human macrophage migration inhibitory factor |
| US5785054A (en) | 1989-06-06 | 1998-07-28 | Kelly; Patrick D. | Genital lubricant with zinc salt, labelled as anti-viral agent |
| GB8915414D0 (en) | 1989-07-05 | 1989-08-23 | Ciba Geigy | Novel cytokines |
| AU634314B2 (en) | 1989-11-13 | 1993-02-18 | Green Cross Corporation, The | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
| US5227459A (en) | 1990-05-18 | 1993-07-13 | Yale University | Synthetic melanin |
| US5786168A (en) | 1990-06-04 | 1998-07-28 | Kirin Beer Kabushiki Kaisha | Method for recombinant production of antigen non-specific glycosylation inhibiting factor (GIF) |
| US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
| US6080407A (en) | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
| US6774227B1 (en) | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
| WO1994026307A1 (en) | 1993-05-17 | 1994-11-24 | The Picower Institute For Medical Research | Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity |
| US5559028A (en) | 1993-05-19 | 1996-09-24 | Antigen Express, Inc. | Methods of enhancing or antigen presentation to T cells inhibiting |
| AU7394294A (en) | 1994-05-16 | 1995-12-05 | Human Genome Sciences, Inc. | Macrophage migration inhibitory factor-3 |
| US5747023A (en) | 1994-07-01 | 1998-05-05 | Genentech, Inc. | Cancer therapy using lymphotoxin |
| SI9400363A (en) | 1994-09-19 | 1996-08-31 | Mozetic Francky Bojana | Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein |
| AU4365796A (en) | 1994-11-16 | 1996-06-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor |
| JPH0977799A (ja) | 1995-09-13 | 1997-03-25 | Sapporo Immuno Diagnostic Lab:Kk | ヒト−マクロファージ遊走阻止因子（ヒト−ｍｉｆ）に対するモノクローナル抗体および該抗体を産生するハイブリドーマ |
| WO1997025344A1 (en) | 1996-01-03 | 1997-07-17 | The Australian National University | Clip analogues and autoimmune disease |
| US6420188B1 (en) | 1996-02-16 | 2002-07-16 | The Picower Institute For Medical Research | Screening assay for the identification of inhibitors for macrophage migration inhibitory factor |
| US6492428B1 (en) | 2000-07-26 | 2002-12-10 | The Picower Institute For Medical Research | Compounds having MIF antagonist activity |
| US5726020A (en) | 1996-06-11 | 1998-03-10 | University Of Massachusetts | Inhibition of II synthesis |
| US6297253B1 (en) | 1996-10-15 | 2001-10-02 | The Picower Institute For Medical Research | Compounds and methods of use to treat infectious diseases |
| US6395276B1 (en) | 1997-05-02 | 2002-05-28 | Immunomedics, Inc. | Immunotoxins directed against malignant cells |
| AU6336398A (en) | 1997-02-24 | 1998-09-09 | Johns Hopkins University, The | Immunomodulatory polypeptides derived from the invariant chain of mhc class ii |
| CA2205680A1 (en) | 1997-05-16 | 1998-11-16 | The University Of Western Ontario | Clip immunomodulatory peptide |
| US6011005A (en) | 1997-09-18 | 2000-01-04 | The Picower Institute For Medical Research | Prevention of pregnancy miscarriages |
| AU747767B2 (en) | 1997-11-05 | 2002-05-23 | University Of Southern California | Use of cytokines and mitogens to inhibit pathological immune responses |
| RU2236251C2 (ru) | 1999-02-12 | 2004-09-20 | Дзе Скриппс Рисерч Инститьют | Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии |
| AU1235601A (en) | 1999-10-29 | 2001-05-14 | Cytokine Pharmasciences, Inc. | Compounds having mif antagonist activity |
| US6268151B1 (en) | 2000-01-20 | 2001-07-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of macrophage migration inhibitory factor expression |
| AU2001238677A1 (en) | 2000-02-28 | 2001-09-12 | Idec Pharmaceuticals Corporation | Method for preparing anti-mif antibodies |
| CA2455915C (en) | 2001-03-29 | 2013-05-14 | Cytokine Pharmasciences, Inc. | Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| US7205107B2 (en) | 2001-12-21 | 2007-04-17 | Cytokine Pharmasciences, Inc. | Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease |
| US20050202010A1 (en) | 2003-08-29 | 2005-09-15 | Giroir Brett P. | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
| US8883160B2 (en) | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| CN105709237A (zh) | 2005-12-16 | 2016-06-29 | Ibc 医药公司 | 基于免疫球蛋白的多价生物活性装配体 |
| CN100457895C (zh) | 2006-05-24 | 2009-02-04 | 中国科学院生物物理研究所 | 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用 |
| ES2531629T3 (es) * | 2008-01-04 | 2015-03-18 | Baxter International Inc. | Anticuerpos anti-MIF |
| EP2079202A1 (en) * | 2008-01-08 | 2009-07-15 | NEC Corporation | Method for optimizing the triggering of the transmission of buffer status reporting (BSR) information |
| JP5786204B2 (ja) | 2010-01-19 | 2015-09-30 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | インスリン様増殖因子ｉ型受容体（ｉｇｆ−１ｒ）を標的とする新規クラスの単一特異性ヒト化抗体および二重特異性ヒト化抗体 |
| AU2012327159B2 (en) | 2011-10-07 | 2015-03-26 | Baxalta GmbH | Characterization of CHO-MIF gene and protein, and use thereof |
| WO2013050453A1 (en) | 2011-10-07 | 2013-04-11 | Baxter Healthcare S.A. | Oxmif as a diagnostic marker |
-
2012
- 2012-10-04 WO PCT/EP2012/069598 patent/WO2013050453A1/en not_active Ceased
- 2012-10-04 JP JP2014533883A patent/JP2014530360A/ja active Pending
- 2012-10-04 EP EP12769097.2A patent/EP2748613B1/en active Active
- 2012-10-04 HK HK14112074.8A patent/HK1198591A1/xx unknown
- 2012-10-04 US US14/350,186 patent/US9958456B2/en active Active
- 2012-10-04 AU AU2012320597A patent/AU2012320597C1/en active Active
- 2012-10-05 TW TW101137028A patent/TW201321408A/zh unknown
- 2012-10-05 AR ARP120103713A patent/AR088244A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2748613A1 (en) | 2014-07-02 |
| AU2012320597A1 (en) | 2013-05-09 |
| EP2748613B1 (en) | 2021-05-05 |
| JP2014530360A (ja) | 2014-11-17 |
| HK1198591A1 (en) | 2015-04-30 |
| AU2012320597C1 (en) | 2015-10-15 |
| AU2012320597B2 (en) | 2015-05-21 |
| US9958456B2 (en) | 2018-05-01 |
| US20140248638A1 (en) | 2014-09-04 |
| WO2013050453A4 (en) | 2013-06-06 |
| WO2013050453A1 (en) | 2013-04-11 |
| TW201321408A (zh) | 2013-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088244A1 (es) | oxMIF COMO MARCADOR DE DIAGNOSTICO | |
| CO6410314A2 (es) | Proteínas de unión a il-17 | |
| NI201200014A (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina - 2 humana | |
| AR092818A1 (es) | Anticuerpo tau humanizado | |
| BR112013010952A2 (pt) | sistemas de rmn e métodos para a detecção rápida de analisados | |
| MX347853B (es) | Ensayo cuantitativo rapido para medir la funcion del regulador de conductancia de transmembrana de fibrosis quistica (cftr) en un molde de cultivo intestinal primario. | |
| MX2018016404A (es) | Anticuerpos de union a cd3. | |
| AR092779A1 (es) | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau | |
| ECSP099547A (es) | Anticuerpos neutralizantes del citomegalovirus humano y su uso | |
| BRPI0807318B8 (pt) | "microrna associado a exossomos como marcador diagnóstico" | |
| DOP2012000299A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| CO6771416A2 (es) | Inmunoglobulinas de dominio variable dual biespecíficas de il-1 alfa y beta y su uso | |
| AR088083A1 (es) | USO DE ANTICUERPOS DE UNION A IL-1b | |
| AR081696A1 (es) | Anticuerpo para el diagnostico y/o pronostico de cancer | |
| BR112016001957A2 (pt) | biossensor | |
| AR063493A1 (es) | Nuevos anticuerpos anti notch 3 y su uso para la deteccion y el diagnostico de enfermedades | |
| ECSP13013092A (es) | Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo | |
| WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
| AR087363A1 (es) | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres | |
| BR112015003957A2 (pt) | alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria | |
| BR112014031957A2 (pt) | bag3 como soro bioquímico e marcador de tecido | |
| BR112013031431A2 (pt) | método para o diagnóstico da doença de gaucher | |
| MX343873B (es) | Ensayo de diagnostico de anticuerpo. | |
| BR112013007041A2 (pt) | animal não humano, descendente, linhagem de células, tecido, explante de órgão, ou cultura dos mesmos, uso do modelo de doenças inflamatórias e métodos para o rastreio de compostos anti-inflamatórios e para a avaliação | |
| BR112017006215A2 (pt) | método para detectar uma proximidade espacial de um primeiro e um segundo epítopos, método para estratificação de um indivíduo, kit para realizar o método, e, uso do kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |